tbuckley/cabot-search huggingface dataset:
Comparison of whole-blood eosinophil counts in extrinsic asthmatics with acute and chronic asthma
Authors: P. H Howarth
Journal: BMJ (1982)

dase activities.The maximum change observed was: 1 U/1-this corresponded to a 16' increase for one subject (6 to 7 U/i) and a 14",, decrease (7 to 6 U/i) for another.When coupled with the allowable limits of error for the y-glutamyltranspeptidase method ( 10", in range 0-20 U/1), however, these changes were not significant.Similarly, no significant changes were found in concentrations of serum aspartate transaminase, another enzyme used in the diagnosis of alcohol related problems.The results of this study indicate that 24 hours after a single low dose of alcohol the activity of y-glutamyltranspeptidase in serum is not appreciably affected and thus would be unlikely to produce mislcading results when used for diagnostic purposes.Our results, like those of Dr Dunbar and others and Shaw,3 contrast with the results of other workers who found a significant increase in serum yglutamyltranspeptidase activity after a dose of alcohol.
Psychiatry in the Functionally Organized Undergraduate Curriculum
Authors: ROBERT E. BECKER, RONALD M. WINTROB, ROBERT CANCRO, JAMES R. STABENAU
Journal: American Journal of Psychiatry (1973)

The functionally organized curriculum permits the integration of psychiatry into most of the courses that comprise the first two years of medical school. Rather than presenting psychiatry to the student as a separate discipline or centering the acquisition of interpersonal skills around specific psychiatric diseases, this system introduces psychiatric concepts in their natural context, as they arise in conjunction with disease in functioning human organ systems.
Norethynodrel and Thromboembolism
Authors: William F. Minogue, Ira C. Halperin, J. Soler-Bechara, Philip Varriale, Frank B. Flood
Journal: New England Journal of Medicine (1963)

THROMBOEMBOLIC disease has been associated with the use of norethynodrel with ethynylestradiol 3-methyl ether (Enovid). It is the purpose of this article to review the available literature and to present a patient in whom the temporal relation between the use of this drug and massive thromboembolism is striking. Documentation by angiocardiography and serial arterial gas studies is provided.Review of the LiteratureSince 1959 norethynodrel with ethynylestradiol 3-methyl ether has been available as a contraceptive for oral use. As of August, 1961, approximately 200,000 women in the United States were taking this drug. This figure reached 1,100,000 in August, 1962. . . .
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review
Authors: Dean T Eurich, Finlay A McAlister, David F Blackburn, Sumit R Majumdar, Ross T Tsuyuki, Janice Varney, Jeffrey A Johnson
Journal: BMJ (2007)

To review the literature on the association between antidiabetic agents and morbidity and mortality in people with heart failure and diabetes.Systematic review and meta-analysis of controlled studies (randomised trials or cohort studies) evaluating antidiabetic agents and outcomes (death and admission to hospital) in patients with heart failure and diabetes.Electronic databases, manual reference search, and contact with investigators.Two reviewers independently extracted data. Risk estimates for specific treatments were abstracted and pooled estimates derived by meta-analysis where appropriate.Eight studies were included. Three of four studies found that insulin use was associated with increased risk for all cause mortality (odds ratio 1.25, 95% confidence interval 1.03 to 1.51; 3.42, 1.40 to 8.37 in studies that did not adjust for diet and antidiabetic drugs; hazard ratio 1.66, 1.20 to 2.31; 0.96, 0.88 to 1.05 in the studies that did). Metformin was associated with significantly reduced all cause mortality in two studies (hazard ratio 0.86, 0.78 to 0.97) compared with other antidiabetic drugs and insulin; 0.70, 0.54 to 0.91 compared with sulfonylureas); a similar trend was seen in a third. Metformin was not associated with increased hospital admission for any cause or for heart failure specifically. In four studies, use of thiazolidinediones was associated with reduced all cause mortality (pooled odds ratio 0.83, 0.71 to 0.97, I2=52%, P=0.02). Thiazolidinediones were associated with increased risk of hospital admission for heart failure (pooled odds ratio 1.13 (1.04 to 1.22), I2=0%, P=0.004). The two studies of sulfonylureas had conflicting results, probably because of differences in comparator treatments. Important limitations were noted in all studies.Metformin was the only antidiabetic agent not associated with harm in patients with heart failure and diabetes. It was associated with reduced all cause mortality in two of the three studies.
Transient Outward Current, <i>I</i> <sub>to1</sub> , Is Altered in Cardiac Memory
Authors: Hangang Yu, David McKinnon, Jane E. Dixon, Junyuan Gao, Randy Wymore, Ira S. Cohen, Peter Danilo, Alexei Shvilkin, Evgeny P. Anyukhovsky, Eugene A. Sosunov, Motoki Hara, Michael R. Rosen
Journal: Circulation (1999)

Cardiac memory refers to an altered T-wave morphology induced by ventricular pacing or arrhythmias that persist for variable intervals after resumption of sinus rhythm.We induced long-term cardiac memory (LTM) in conscious dogs by pacing the ventricles at 120 bpm for 3 weeks. ECGs were recorded daily for 1 hour, during which time pacing was discontinued. At terminal study, the heart was removed and the electrophysiology of left ventricular epicardial myocytes was investigated. Control (C) and LTM ECG did not differ, except for T-wave amplitude, which decreased from 0.12+/-0.18 to -0.34+/-0.21 mV (+/-SEM, P<0.05), and T-wave vector, which shifted from -37+/-12 degrees to -143+/-4 degrees (P<0.05). Epicardial action potentials revealed loss of the notch and lengthening of duration at 20 days (both P<0.05). Calcium-insensitive transient outward current (Ito) was investigated by whole-cell patch clamp. No difference in capacitance was seen in C and LTM myocytes. Ito activated on membrane depolarization to -25+/-1 mV in C and -7+/-1 mV (P<0.05) in LTM myocytes, indicating a positive voltage shift of activation. Ito density was reduced in LTM myocytes, and a decreased mRNA level for Kv4.3 was observed. Recovery of Ito from inactivation was significantly prolonged: it was 531+/-80 ms (n=10) in LTM and 27+/-6 ms (n=9) in C (P<0.05) at -65 mV.Ito changes are associated with and can provide at least a partial explanation for action-potential and T-wave changes occurring with LTM.
Patient With Chronic Myeloid Leukemia in Complete Cytogenetic Response: What Does It Mean, and What Does One Do Next?
Authors: David Marin
Journal: Journal of Clinical Oncology (2014)

Article Tools ONCOLOGY GRAND ROUNDS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2013.52.9230 Journal of Clinical Oncology - published online before print January 13, 2014 PMID: 24419129 Patient With Chronic Myeloid Leukemia in Complete Cytogenetic Response: What Does It Mean, and What Does One Do Next? David MarinxDavid MarinSearch for articles by this author Show More Imperial College London, Hammersmith Hospital, London, United Kingdom https://doi.org/10.1200/JCO.2013.52.9230 First Page Full Text PDF Figures and Tables © 2014 by American Society of Clinical Oncology
Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial
Authors: Thomas Pilgrim, Dik Heg, Marco Roffi, David Tüller, Olivier Muller, André Vuilliomenet, Stéphane Cook, Daniel Weilenmann, Christoph Kaiser, Peiman Jamshidi, Therese Fahrni, Aris Moschovitis, Stéphane Noble, Franz R Eberli, Peter Wenaweser, Peter Jüni, Stephan Windecker
Journal: The Lancet (2014)
Obituary of Hamilton Naki: Clarification is certainly needed
Authors: Mike Ebdy
Journal: BMJ (2005)

Junior doctors' shifts and sleep deprivation New on-call rotas do not workEditor-Clearly the editorial by Murray et al on junior doctors' shifts has struck a chord with many, as on-call rotas are something close to many doctors hearts. 1 2 To most it seems the grass is not greener on the other side.Having worked most rotas, be it a traditional one in four, with full weekends, to partial, hybrid, and full shift patterns, I am in a reasonable position to comment on what I think makes a liveable on-call rota.I was under the impression that the European Working Time Directive was set out to improve the health and safety of workers, make working conditions better, but also make life away from work better because doctors would be less tired.The directive scores a "no" against all of these.I find myself more tired at work and at home, less enthusiastic, and less motivated by what is becoming a regular chore.Instead of being on call once a week, I find myself doing an on-call shift two or three times a week (on average), being late home more often than not because fewer juniors are around, and spending less time with my young children.The "old" rota system of a 24 hour oncall, with at least six on a rota, made on-call shifts less frequent, more tolerable, and even enjoyable.It also left plenty of time for training, and so long as there were six or more on rota, it made the annual leave far more flexible and workable.Anaesthetists rarely complained, certainly compared with other specialties' rotas, and everyone knew that however busy, you were always going to go home to a full day off in the morning.Why not listen to those doing the rota, and affected family members, and respect within reason what the workers want to work.
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
Authors: Samantha C. Gouw, H. Marijke van den Berg, Johannes Oldenburg, Jan Astermark, Philip G. de Groot, Maurizio Margaglione, Arthur R. Thompson, Waander van Heerde, Jorien Boekhorst, Connie H. Miller, Saskia le Cessie, Johanna G. van der Bom
Journal: Blood (2012)
Infections in Long-Term Care Facilities
Authors: FREDRICK T. SHERMAN
Journal: Annals of Internal Medicine (1979)

Letters and Corrections1 May 1979Infections in Long-Term Care FacilitiesFREDRICK T. SHERMAN, M.D., LESLIE S. LIBOW, M.D.FREDRICK T. SHERMAN, M.D.Search for more papers by this author, LESLIE S. LIBOW, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-90-5-855_3 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: We have just completed our report on infection surveillance in a skilled nursing facility (1) and were struck by the absence of such a focus in the National Institute of Allergy and Infectious Disease's recent symposium, "The Impact of Infection on Medical Care in the United States: Problems and Priorities for Future Research" (2).The symposium addressed itself mainly to bacterial infections acquired in the community as well as in the one million acute hospital beds in this country. None of the authors who discussed problems needing clinical investigation referred to infection surveillance or control among approximately...References1. SHERMANTUCCILIBOW FVL: Nosocomial urinary tract infections in a skilled nursing facility. 31st Annual Scientific Meeting of the Gerontological Society 1978 Google Scholar2. KUNINEDELMAN CR (eds.): The impact of infections on medical care in the United States. Problems and priorities for future research. Ann Intern Med 89:737-866, 1978 Google Scholar3. VALENTITRUDELLBENTLY WRD: Factors predisposing to oropharyngeal colonization with gram-negative bacilli in the aged. N Engl J Med 298:1108-1111, 1978 CrossrefMedlineGoogle Scholar4. GARBBROWNGARBTUTHILL JRJR: Differences in etiology of pneumonias in nursing home and community patients. JAMA 240:2169-2173, 1978 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Division of Geriatric Medicine Jewish Institute for Geriatric Care at Long Island Jewish Hillside Medical Center School of Medicine State University of New York at Stony Brook New Hyde Park, NY 11042 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByExtended Care FacilityNosocomial Infections on a Rehabilitation Unit in an Acute Care HospitalSystemic Antibiotic Use in Nursing Homes: A Quality AssessmentPrevalence Survey of Infections and Their Predisposing Factors at a Hospital-Based Nursing Home Care UnitAn Outbreak of Streptococcus pyogenes Infections in a Nursing HomeFREDERICK L. RUBEN, M.D., CARL W. NORDEN, M.D., BARBARA HEISLER, R.N., YVONNE KORICAInfectious Diseases in the ElderlyEDWARD L. SCHNEIDER, M.D. 1 May 1979Volume 90, Issue 5Page: 855-856KeywordsAllergy and immunologyForecastingInfectious disease surveillanceLong-term care Issue Published: 1 May 1979 PDF DownloadLoading ...
Doctors opposed to NHS reforms set up a new political party
Authors: I. Torjesen
Journal: BMJ (2012)

<h3>Objective:</h3> To examine the frequency and determinants of re-infarction after thrombolytic treatment of ST-elevation myocardial infarction (STEMI). <h3>Design:</h3> Observational study of national registry. <h3>Setting:</h3> Emergency ambulance services and admitting hospitals in England and Wales. <h3>Patients:</h3> 35 356 patients with STEMI given thrombolytic treatment in 2005–6. <h3>Main outcome measures:</h3> Re-infarction during hospital admission. <h3>Results:</h3> For 22 391 patients (63.3%) the presence or absence of re-infarction was recorded, and 1460 (6.5%) had re-infarction. Re-infarction rates with in-hospital treatment were similar for reteplase (6.5%) and tenecteplase (6.4%). When the interval from pre-hospital treatment to hospital arrival was greater than 30 minutes re-infarction rates were 12.5% for reteplase, and 11.4% for tenecteplase. Overall, re-infarction rates were higher after pre-hospital treatment with tenecteplase than reteplase (9.6% vs 6.6%, p = 0.005). After multivariate analysis independent predictors of re-infarction for tenecteplase were pre-hospital treatment, OR 1.44 (95% CI 1.21 to 1.71, p&lt;0.001) and weight in the highest quartile compared to the lowest, OR 1.66 (95% CI 1.19 to 2.31, p = 0.003). For reteplase neither factor predicted re-infarction. Bleeding was less common with pre-hospital treatment—overall 1.8% against 3.1%; intracerebral bleeding 0.4% against 0.7%. <h3>Conclusion:</h3> Pre-hospital treatment with tenecteplase was associated with higher re-infarction rates. Longer intervals from pre-hospital treatment to arrival in hospital were associated with high re-infarction rates for both tenecteplase and reteplase. Differences in the use of adjunctive anti-thrombotic therapy in the two treatment environments may underlie the differences in re-infarction rates and bleeding complications observed between pre-hospital and in-hospital thrombolytic treatment.
Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
Authors: Beth Y. Karlan, Amit M. Oza, Gary E. Richardson, Diane M. Provencher, Vincent L. Hansen, Martin Buck, Setsuko K. Chambers, Prafull Ghatage, Charles H. Pippitt, John V. Brown, Allan Covens, Raj V. Nagarkar, Margaret Davy, Charles A. Leath, Hoa Nguyen, Daniel E. Stepan, David M. Weinreich, Marjan Tassoudji, Yu-Nien Sun, Ignace B. Vergote
Journal: Journal of Clinical Oncology (2011)

To estimate the efficacy and toxicity of AMG 386, an investigational peptide-Fc fusion protein that neutralizes the interaction between the Tie2 receptor and angiopoietin-1/2, plus weekly paclitaxel in patients with recurrent ovarian cancer.Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer were randomly assigned 1:1:1 to receive paclitaxel (80 mg/m(2) once weekly [QW], 3 weeks on/1 week off) plus intravenous AMG 386 10 mg/kg QW (arm A), AMG 386 3 mg/kg QW (arm B), or placebo QW (arm C). The primary end point was progression-free survival (PFS). Secondary end points included overall survival, objective response, CA-125 response, safety, and pharmacokinetics.One hundred sixty-one patients were randomly assigned. Median PFS was 7.2 months (95% CI, 5.3 to 8.1 months) in arm A, 5.7 months (95% CI, 4.6 to 8.0 months) in arm B, and 4.6 months (95% CI, 1.9 to 6.7 months) in arm C. The hazard ratio for arms A and B combined versus arm C was 0.76 (95% CI, 0.52 to 1.12; P = .165). Further analyses suggested an exploratory dose-response effect for PFS across arms (Tarone's test, P = .037). Objective response rates for arms A, B, and C were 37%, 19%, and 27%, respectively. The incidence of grade ≥ 3 adverse events (AEs) in arms A, B, and C was 65%, 55%, and 64%, respectively. Frequent AEs included hypertension (8%, 6%, and 5% in arms A, B, and C, respectively), peripheral edema (71%, 51%, and 22% in arms A, B, and C, respectively), and hypokalemia (21%, 15%, and 5% in arms A, B, and C, respectively). AMG 386 exhibited linear pharmacokinetic properties at the tested doses.AMG 386 combined with weekly paclitaxel was tolerable, with a manageable and distinct toxicity profile. The data suggest evidence of antitumor activity and a dose-response effect, warranting further studies in ovarian cancer.
Is CD30 (Ki‐1) immunostaining in cutaneous eruptions useful as a marker of Th1 to Th2 cytokine switching and/or as a marker of advanced HIV‐1 disease?
Authors: None Smith, None Barrett, None Neafie, None Tomaszewski, None Yeager, None Nelson, None Wagner, None Skelton
Journal: British Journal of Dermatology (1998)

CD30 is a member of the tumour necrosis factor/nerve growth factor receptor superfamily, which is expressed on CD4+ and CD8+ T-cell clones which produce T helper (Th) 2-type cytokines. It has been proposed that disease progression in HIV-1 is associated with Th1 to Th2 cytokine switching. In 70 cutaneous biopsies from HIV-1 positive patients in different stages of disease, we performed a battery of immunohistochemical stains. These included antibodies to CD3, UCHL-1, OPD-4, L-26, KP-1 and CD30 (Ki-1). In addition, we used a similar battery of stains on cutaneous biopsies of HIV-1 negative patients with inflammatory dermatoses which are established as Th1 or Th2 dominant, e.g. polar leprosy. CD30+ cells were rarely present in early stages of HIV-1 disease, but commonly present in later stages of disease. However, there were cases of late HIV-1 disease which did not contain CD30+ cells. Increased numbers of CD30+ cells were more commonly seen in later stages of HIV-1 disease. However, the expression of CD30 appeared to be better in predicting other established Th2 cutaneous infiltrates in HIV-1 negative patients than in predicting a Th2 cutaneous cytokine pattern in advanced HIV-1 disease.
Miniprobe EUS in the pretherapeutic assessment of early esophageal neoplasia
Authors: M. Chemaly, O. Scalone, G. Durivage, B. Napoleon, B. Pujol, C. Lefort, V. Hervieux, J. Scoazec, J. Souquet, T. Ponchon
Journal: Endoscopy (2007)

See also: Commentaire de travail de M. Chemaly et al., pp. 2Endoscopy 2008; 40(01): 88-88DOI: 10.1055/s-0032-1306798
Contraception and pregnancy in cystic fibrosis
Authors: Jg Thorpe-Beeston
Journal: Journal of the Royal Society of Medicine (2009)

The increasing adult population of those affected by cystic fibrosis (CF) has inevitably increased the number of women with the condition capable of falling pregnant. Indeed, as in the non‐CF population, it should be assumed that all women with the disease should be considered fertile unless proven otherwise. Similarly although 95% of men with CF are infertile due to congenital absence of the vas deferens, active spermatogenesis does occur and it is essential that all men are counselled about their potential fertility before they consider themselves infertile.
Psychiatric Presentations of Medical Illness: Somatopsychic Disorders
Authors: John J. Massarelli
Journal: JAMA (1981)

ABSTRACT In his foreword to this book, Professor Louis A. Faillace says, Psychiatry finds itself at a crossroad. We have to decide what kind of discipline we are going to be. Are we to stay in medicine, or are we to gravitate in many diverse areas and become primarily a collection of social sciences? To many of us, it is very clear that we are  first and then psychiatrists. Dr Richard C. W. Hall and his colleagues have written Psychiatric Presentations of Medical Illness: Somatopsychic Disorders to demonstrate that physicians must regard the mind... in a manner similar to other organ systems, realizing that psychiatric symptoms are nonspecific and may occur as the result of medical as well as psychiatric disorders.After a brief overview of medically induced psychiatric disease, there follow six chapters on psychiatric symptoms that may be part of organic diseases. The point is convincingly made that
Maintenance of Certification
Authors: Antoinette Spevetz
Journal: Annals of Internal Medicine (2015)

Letters6 January 2015Maintenance of CertificationAntoinette Spevetz, MDAntoinette Spevetz, MDFrom Cooper University Hospital, Camden, New Jersey.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L15-5040-6 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I have been following the discussions about the changes in the ABIM MOC program that went into effect in January 2014. In contrast to Baron and Johnson's commentary (1) in support of these changes, Centor and colleagues' accompanying editorial (2) suggests that heuristics are at play, resulting in a disconnect between the intentions of the ABIM and the perceptions of the internal medicine community for whom MOC is one of many mounting stressors. Medicine and the external influences on physicians have certainly changed dramatically since the 1990s when I started to practice. Electronic health records, the rigors ...References1. Baron RJ, Johnson D. The American Board of Internal Medicine: evolving professional self-regulation. Ann Intern Med. 2014;161:221-3. [PMID: 24821363] doi:10.7326/M13-2478 LinkGoogle Scholar2. Centor RM, Fleming DA, Moyer DV. Maintenance of certification: beauty is in the eyes of the beholder [Editorial]. Ann Intern Med. 2014;161:226-7. [PMID: 24821483] doi:10.7326/M14-1014 LinkGoogle Scholar Author, Article, and Disclosure InformationAuthors: Antoinette Spevetz, MDAffiliations: From Cooper University Hospital, Camden, New Jersey.Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterest Forms.do?msNum=L14-0501. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoMaintenance of Certification: Beauty Is in the Eyes of the Beholder Robert M. Centor , David A. Fleming , and Darilyn V. Moyer Maintenance of Certification: Beauty Is in the Eyes of the Beholder Robert M. Centor , David A. Fleming , and Darilyn V. Moyer Maintenance of Certification Michael Kelley Maintenance of Certification Edward Ringel Maintenance of Certification Donald Trainor Maintenance of Certification Robert B. Copeland Maintenance of Certification Leonard Johnson Maintenance of Certification Robert M. Centor , David A. Fleming , and Darilyn V. Moyer Maintenance of Certification Michael Kelley Maintenance of Certification Leonard Johnson Maintenance of Certification Robert M. Centor , David A. Fleming , and Darilyn V. Moyer Maintenance of Certification Robert B. Copeland Maintenance of Certification Donald Trainor Maintenance of Certification Edward Ringel Metrics 6 January 2015Volume 162, Issue 1Page: 79KeywordsConflicts of interestDisclosureElectronic medical recordsMedicarePerception ePublished: 6 January 2015 Issue Published: 6 January 2015 Copyright & PermissionsCopyright © 2015 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...